GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Jingxin Pharmaceutical Co Ltd (SZSE:002020) » Definitions » Beneish M-Score

Zhejiang Jingxin Pharmaceutical Co (SZSE:002020) Beneish M-Score : -1.95 (As of Apr. 22, 2025)


View and export this data going back to 2004. Start your Free Trial

What is Zhejiang Jingxin Pharmaceutical Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -1.95 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Zhejiang Jingxin Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

SZSE:002020' s Beneish M-Score Range Over the Past 10 Years
Min: -2.97   Med: -2.38   Max: -1.56
Current: -1.95

During the past 13 years, the highest Beneish M-Score of Zhejiang Jingxin Pharmaceutical Co was -1.56. The lowest was -2.97. And the median was -2.38.


Zhejiang Jingxin Pharmaceutical Co Beneish M-Score Historical Data

The historical data trend for Zhejiang Jingxin Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Jingxin Pharmaceutical Co Beneish M-Score Chart

Zhejiang Jingxin Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.31 -1.72 -2.63 -2.46 -1.95

Zhejiang Jingxin Pharmaceutical Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.46 -2.75 -2.18 -2.05 -1.95

Competitive Comparison of Zhejiang Jingxin Pharmaceutical Co's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Jingxin Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang Jingxin Pharmaceutical Co's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhejiang Jingxin Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Zhejiang Jingxin Pharmaceutical Co's Beneish M-Score falls into.


;
;

Zhejiang Jingxin Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Zhejiang Jingxin Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.3441+0.528 * 1.012+0.404 * 1.3673+0.892 * 1.0399+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9056+4.679 * -0.001675-0.327 * 0.965
=-1.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Total Receivables was ¥896 Mil.
Revenue was 949.807 + 1058.823 + 1089.261 + 1060.66 = ¥4,159 Mil.
Gross Profit was 438.289 + 531.114 + 558.477 + 550.322 = ¥2,078 Mil.
Total Current Assets was ¥2,905 Mil.
Total Assets was ¥8,479 Mil.
Property, Plant and Equipment(Net PPE) was ¥2,188 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥647 Mil.
Total Current Liabilities was ¥2,135 Mil.
Long-Term Debt & Capital Lease Obligation was ¥23 Mil.
Net Income was 136.949 + 172.89 + 230.915 + 171.208 = ¥712 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 113.468 + 136.528 + 122.636 + 353.529 = ¥726 Mil.
Total Receivables was ¥641 Mil.
Revenue was 1073.298 + 988.985 + 976.127 + 960.426 = ¥3,999 Mil.
Gross Profit was 530.383 + 513.793 + 498.138 + 480.032 = ¥2,022 Mil.
Total Current Assets was ¥3,354 Mil.
Total Assets was ¥7,987 Mil.
Property, Plant and Equipment(Net PPE) was ¥2,300 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥687 Mil.
Total Current Liabilities was ¥2,075 Mil.
Long-Term Debt & Capital Lease Obligation was ¥31 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(895.601 / 4158.551) / (640.718 / 3998.836)
=0.215364 / 0.160226
=1.3441

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2022.346 / 3998.836) / (2078.202 / 4158.551)
=0.505734 / 0.499742
=1.012

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2904.776 + 2188.398) / 8479.313) / (1 - (3353.735 + 2300.196) / 7986.557)
=0.399341 / 0.292069
=1.3673

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=4158.551 / 3998.836
=1.0399

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 2300.196)) / (0 / (0 + 2188.398))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(647.04 / 4158.551) / (687.045 / 3998.836)
=0.155593 / 0.171811
=0.9056

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((23.131 + 2134.52) / 8479.313) / ((31.228 + 2074.759) / 7986.557)
=0.254461 / 0.263691
=0.965

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(711.962 - 0 - 726.161) / 8479.313
=-0.001675

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Zhejiang Jingxin Pharmaceutical Co has a M-score of -1.95 suggests that the company is unlikely to be a manipulator.


Zhejiang Jingxin Pharmaceutical Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Zhejiang Jingxin Pharmaceutical Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang Jingxin Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No.800 Xinchang East Road, Yulin subdistrict, Zhejiang Province, Xinchang, CHN, 312500
Zhejiang Jingxin Pharmaceutical Co Ltd is an integrated pharmaceuticals enterprise that focuses on manufacturing, R&D, and marketing. It offers finished dosage forms which include tablets, capsules, and injections in the areas of antilipemic, antidiabetic, cholesterolemia, luoroquinolones, cephalosporin, gastrointestinal promotion, anti-inflammatory analgesic, and antibiotics; APIs, and Chinese herbal drugs. The products are sold to overseas markets such as South-east of Asia, South Asia, Latin America and Europe.
Executives
Wang Neng Neng Director
Chen Shao Bi Executives
Wang Guang Qiang Supervisors
Lv Gang Director
Zhou Lin Executives
Yu Yi Ping Supervisors
Chen Mei Li Directors, executives
Zhang Li Wa Directors, executives
Wu Zheng Jie Director

Zhejiang Jingxin Pharmaceutical Co Headlines

No Headlines